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Introduction
Multiple myeloma is caused by proliferation of monoclonal plasma cells in the
bone marrow and is the second most common hematologic malignancy.1 The
treatment options have improved markedly in recent years and led to prolonged
survival.2 However, the disease is still considered to be incurable. The typical
course of multiple myeloma is repeated treatment responses followed by increas-
ingly aggressive relapses. Ultimately, the disease becomes refractory to all treat-
ment and the patient dies. 
To assess disease progression and treatment response, clinicians rely on monitor-
ing of the monoclonal immunoglobulin (M protein) secreted by the tumor cells as a
biomarker for tumor mass.3,4 However, some patients escape the traditional moni-
toring. Between 1-3% of patients have non-secretory multiple myeloma and no
Circulating tumor DNA is a promising biomarker to monitor tumorload and genome alterations. We explored the presence of circu-lating tumor DNA in multiple myeloma patients and its relation
to disease activity during long-term follow-up. We used digital droplet
polymerase chain reaction analysis to monitor recurrent mutations,
mainly in mitogen activated protein kinase pathway genes NRAS, KRAS
and BRAF. Mutations were identified by next-generation sequencing or
polymerase chain reaction analysis of bone marrow plasma cells, and
their presence analyzed in 251 archived serum samples obtained from 20
patients during a period of up to 7 years. In 17 of 18 patients, mutations
identified in bone marrow during active disease were also found in a
time-matched serum sample. The concentration of mutated alleles in
serum correlated with the fraction in bone marrow plasma cells (r=0.507,
n=34, P<0.002). There was a striking covariation between circulating
mutation levels and M protein in ten out of 11 patients with sequential
samples. When relapse evaluation by circulating tumor DNA and M pro-
tein could be directly compared, the circulating tumor DNA showed
relapse earlier in two patients (3 and 9 months), later in one patient (4
months) and in three patients there was no difference. In three patients
with transformation to aggressive disease, the concentrations of muta-
tions in serum increased up to 400 times, an increase that was not seen
for the M protein. In conclusion, circulating tumor DNA in myeloma is a
multi-faceted biomarker reflecting mutated cells, total tumor mass and
transformation to a more aggressive disease. Its properties are both sim-
ilar and complementary to M protein. 
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ABSTRACT
detectable M protein.5,6 Furthermore, 10% of newly diag-
nosed myeloma patients have oligo-secretory disease,
defined as a baseline level of M protein that is too low to
evaluate treatment response reliably by traditional meth-
ods.3,7 These patients are challenging to monitor and are,
therefore, often denied access to clinical trials.7
A promising new cancer biomarker is circulating tumor
DNA (ctDNA), which may be extracted from serum or
plasma.8 DNA fragments are released from cancer cells as
well as normal cells in the body during apoptosis and
necrosis.9,10 The cancer-derived fragments may be identi-
fied if they contain tumor-specific mutations or other
genetic aberrations.8 In studies of solid tumors, ctDNA
has provided information about tumor mass and residual
disease, as well as information about the tumor genome
that could otherwise only have been obtained by a tumor
biopsy.11-15 Information about ctDNA in multiple myelo-
ma lags behind as only a single study has so far been pub-
lished.16
The somatic mutational landscape of multiple myeloma
has been described in several studies.17-21 Out of more than
6,000 genes in which coding mutations have been identi-
fied, 13 are mutated more frequently than predicted from
the background mutation rate, suggesting that they are
implicated in the development of the disease.17,18 Among
these recurrently mutated genes, NRAS, KRAS and BRAF
in the mitogen activated protein (MAP) kinase pathway
are most frequently mutated, occurring in bone marrow
plasma cells from approximately 50% of patients at diag-
nosis. Moreover, activating mutations in the MAP kinase
pathway are of interest because they are potential thera-
peutic targets.22-25
In this study, we explored ctDNA as a biomarker of
multiple myeloma and focused on mutations in recurrent-
ly mutated genes including NRAS, KRAS and BRAF. We
measured the concentrations of specific mutations in
serum through several responses and relapses for up to 7
years in 20 patients and found a remarkable covariation
with the concentration of M protein. However, in terminal
aggressive disease, ctDNA appears to reflect the develop-
ment of the disease better.
Methods
Study design and patients
We conducted a retrospective study measuring ctDNA in
archived serum samples from patients with multiple myeloma.
Mutations of interest were identified in a bone marrow biopsy or
purified bone marrow plasma cells and subsequently measured in
serum by mutation-specific digital droplet polymerase chain reac-
tion (ddPCR). Patients were included based on the following crite-
ria: (i) presence of one or more mutations in genes recurrently
mutated in myeloma17,18 and (ii) availability of relevant serum or
plasma samples. Twenty patients from two sources were included
in this study: one previously published study of the BRAFV600E
mutation in myeloma and an on-going whole exome sequencing
(WES) study.26 A flowchart describing the patients’ inclusion in
detail is presented in the Online Supplementary Material (Online
Supplementary Figure S1).
Clinical data were obtained from the patients’ records and
archived blood smears were evaluated for the presence of plasma
cells. All patients had given written consent. The study was
approved by the Regional Committee for Medical and Health
Research Ethics (2016/821). 
Details about the following experimental procedures are provid-
ed in the Online Supplementary Methods.
Detection of mutations in serum by digital droplet
polymerase chain reaction
Serum (n=249) and citrate-plasma (n=2) samples were obtained
from the Norwegian Multiple Myeloma Biobank. DNA was
extracted from a median sample volume of 1.8 mL (range, 0.4-3
mL) using a QiaAmp Circulating Nucleic Acid kit (Qiagen, Hilden,
Germany). To detect mutations, we used the ddPCR system
QX100/200 from Bio-Rad Laboratories (Hercules, CA, USA).27
Detailed assay information is presented in Online Supplementary
Table S1 and raw data examples in Online Supplementary Figure S2.
Patients’ samples were considered to be mutation-positive if the
mutant concentration in the sample was higher than the 95% con-
fidence interval of the assay-specific false positive rate (Online
Supplementary Table S2, Online Supplementary Figure S3). The esti-
mated number of mutant copies required in a sample to be consid-
ered mutation-positive ranged from 0.84 to 2.96 copies of mutated
DNA (median 1.4). The quantity of mutated DNA in positive sam-
ples was reported in copies per mL of serum. 
Whole exome sequencing
WES of purified plasma cells and matched germline controls
was performed as previously described.26 The target coverage of
>100x was achieved for 85% of exonic regions. The limit of detec-
tion of WES was a mutated allele fraction of 2-4 % in the bone
marrow sample. 
Statistical analysis
Bivariate correlations were performed by the Spearman correla-
tion rank test. The level of statistical significance with two-tailed
P-values was P<0.05. Statistical analyses were carried out in SPSS
v. 21 (IBM Corporation, Armonk, NY, USA).
Results
A summary of clinical and mutational data for each
patient is given in Table 1.
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Figure 1. Correlation between mutation levels in bone marrow plasma cells
and serum samples. Time-matched bone marrow and serum samples were
obtained within 10 days of each other. Purified bone marrow plasma cells were
analyzed by WES. In three cases in which WES was negative, positive results
from the more sensitive ddPCR of bone marrow plasma cells were reported
instead. Serum samples were analyzed by ddPCR.
Relation between tumor mutations in serum and bone
marrow plasma cells
We started by determining whether mutations found in
bone marrow plasma cells could be detected in time-
matched serum samples by ddPCR, and found that this
was the case for 17 of 18 patients (34 of 35 mutations). We
examined the quantitative relationship between the con-
centrations of circulating mutated DNA and the allele frac-
tions of the same mutations in bone marrow plasma cells.
There was a moderate positive correlation between the
two (r=0.507, n=34, P<0.002) (Figure 1). Thus, the concen-
tration of a mutation in serum reflects the fraction of
tumor cells harboring the same mutation. 
Relation between levels of recurrent mutations and M
protein in serum 
Eleven patients had sequential serum samples available,
spanning a median of 50 months (range, 8-90). In these
patients, we monitored the concentration of mutated
DNA over time in relation to tumor mass and treatment
response as evaluated by M protein concentration. All 11
patients had a MAP kinase pathway mutation and two
had at least one additional mutation (Table 1, patients 1-
11). Most of these mutations were highly present in the
bone marrow at diagnosis, with 75-100% mutation-posi-
tive plasma cells by immunohistochemistry or >50%
mutated allele fraction by WES. Slightly lower MAP
kinase mutated allele fractions of 34% and 26% were
found at diagnosis in patients 2 and 5, respectively, and
patient 11 had 25-50% BRAFV600E-mutated cells by
immunohistochemistry. No diagnostic bone marrow sam-
ples were available from patients 9 and 10.
The concentrations of MAP kinase mutations in serum
showed marked covariation with M protein levels. For
example, patient 1 (Figure 2A) was monitored by M pro-
tein as well as circulating BRAFV600E mutation during 51
months, from diagnosis through five relapses until death.
Every change in disease activity, as reflected by the M pro-
tein level, was accompanied by similar changes in serum
BRAFV600E mutation levels. Similar observations were made
in ten of the 11 patients with available sequential samples
(Figures 2 and 3 and Online Supplementary Figure S4). The
observed covariation in ten patients was confirmed by a
formal correlation analysis of 210 time-matched measure-
ments of M protein and circulating MAP kinase pathway
mutation with correlation coefficients ranging from 0.63
to 0.96 (Online Supplementary Table S3). Only in patient 10
(Online Supplementary Figure S4B) was there no correlation.
In this patient the BRAFV600E mutation became undetectable
after being present at a very low concentration (<10
copies/mL) at an early time point. 
An important aspect of ctDNA analysis in myeloma is
its sensitivity, compared to conventional methods, to
detect low levels of disease. When looking at the ability to
E.H. Rustad et al.
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Table 1. Summary of clinical data and mutations. 
Patient Mutation(s) Sex Age Survival N. of M-Protein ISS-stage Hb Ca-corr Creatinine Bone
(years) (months) treatments (g/dL) (mmol/L ) (μmol/L) disease
1 BRAF V600E M 69 51 6 IgA kappa - - - - -
2 NRAS Q61K F 66 40 4 IgA kappa 3 8.7 2.53 105 Yes
3 KRAS Q61H F 77 35* 2 IgG kappa 2 11.9 2.71 58 No
4 FAM46C S27Y,  F 54 52 6 IgG kappa 2 11.9 2.31 71 -
IRF4 K123R, 
KRAS A146P
5 KRAS Q61R, M 58 9 2 IgG kappa 1 15.3 2.42 54 -
TP53 Y236N
6 BRAF V600E F 81 64 2 IgG kappa 3 12.8 2.51 94 Yes
7 BRAF V600E M 57 77 10 IgG lambda - 11.9 - 107 No
8 BRAF V600E F 68 104* 3 IgG lambda 1 14.2 2.26 60 Yes
9 KRAS Q22K F 61 107 9 IgG lambda 2 10.9 2.36 61 Yes
10 BRAF V600E M 54 79 6 Lambda 1 14.1 2.53 70 Yes
11 BRAF V600E M 75 22 3 Lambda 3 7.8 3.53 248 No
12 NRAS G12D F 48 58* 4 IgA kappa - 10.9 - 82 Yes
13 NRAS Q61K M 67 55* 2 IgA kappa 3 9.9 3.2 81 -
14 DIS3 H788R,  M 73 24 3 IgA kappa 1 14.5 2.31 93 Yes
NRAS Q61R
15 NRAS G12A M 68 23* 2 IgG kappa 1 14.1 2.23 30 -
16 NRAS Q61R M 61 33* 2 IgA lambda 2 9.4 - - Yes
17 NRAS Q61K M 50 32* 2 IgA kappa 2 12.3 2.76 97 No
18 KRAS Q22K F 83 28* 3 IgA kappa 3 12.6 2.27 63 Yes
19 BRAF V600E, F 69 46* 1 IgA lambda 2 10 2.44 79 Yes
NRAS Q61K
20 BRAF V600E M 64 42 2 Lambda 2 11.3 2.85 125 Yes
Clinical parameters are reported from the time of diagnosis of multiple myeloma. Survival is calculated from the date of diagnosis to the date of death or last observation. M:
male; F: female; *: patient still alive; -: missing data; ISS: International staging System; Ca-corr: albumin-corrected serum calcium; Hb: hemoglobin.
predict relapse, we found that serum mutation levels tend-
ed to increase before or at the same time as M protein in
most cases in which the two methods could be compared
(Figures 2 and 3 and Online Supplementary Figure S4).
Notably, a relapse from complete remission in patient 2
(Figure 2B) was detected by ctDNA 9 months before M
protein became detectable. Relapses were also detected
earlier by ctDNA in patient 1 (Figure 2A), although with
somewhat shorter lead-times. On the other hand, in
patient 11 (Online Supplementary Figure S4F) the second
relapse was heralded by an increase in urine M protein 4
months before ctDNA became detectable. Furthermore,
ctDNA often became undetectable during periods of
remission even though low levels of M protein were still
detectable, or the concentration of ctDNA would fluctuate
around the limit of detection. In summary, ctDNA
showed relapse earlier in two patients (3 and 9 months),
later in one patient (4 months) and in three patients there
was no difference.
In patient 3 (Figure 2C), we initially detected a KRASQ61H
mutation in plasma cells by WES as well as by ddPCR of
serum. Light chain escape occurred at the second relapse,
38 months after the start of treatment, when the tumor
cell secretion converted from IgA-κ to κ chains only.
Despite this change, we could monitor the disease by the
serum concentration of KRASQ61H mutation. 
In two patients, we monitored one or two recurrent
mutations in addition to the MAP kinase pathway muta-
tions (Figure 3A,B). Patient 4 (Figure 3A) had an IRF4
mutation highly present in bone marrow plasma cells at
the last relapse. At diagnosis, this mutation was not
detected in plasma cells by WES, but a few copies were
found by ddPCR of plasma cells and serum. The concen-
tration of the mutation in serum increased abruptly after
initiation of therapy and covaried with M protein level for
the rest of the disease course. Conversely, a FAM46C
mutation present at a 60% allele fraction in plasma cells at
diagnosis became undetectable in both serum and plasma
cells during the disease course. In patient 5 (Figure 3B), the
concentrations of M protein and KRAS and TP53 muta-
tions followed similar patterns in serum, despite a plasma
cell allele fraction of only 4% for the TP53 mutation at
diagnosis. 
Altogether, we monitored 14 mutated clones in 11
patients. Twelve of the mutations were detectable in
serum at each relapse and covaried with M protein,
whereas two mutations became undetectable during the
disease course (FAM46CS279N in patient 4 and BRAFV600E in
patient 10). These observations suggest that the serum
concentration of recurrent mutations over long periods of
time reflect the changes in total tumor mass in most
myeloma patients.
Serum mutation levels in aggressive disease
In patients 1, 4, and 5 (Figure 2A, Figure 3 A,B) we
noticed a marked increase in serum mutation levels in the
Monitoring myeloma by mutations in serum
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Figure 2. Sequential levels of M protein and circulating MAP kinase
pathway mutations. Sequential serum concentrations of M protein
and MAP kinase pathway mutations through the disease course are
shown for three patients (panels A-C depict patients 1-3) along with
the type and duration of treatment. For patient 3, there were no
serum samples collected between 10 and 38 months. Axis legends
for all panels are the same as for panel A. X, time of death.
Treatments: M: melphalan; P: prednisone; T: thalidomide; V: borte-
zomib; D: dexamethasone; L: lenalidomide; C: cyclophosphamide;




terminal phase of the disease. At that time the patients
had treatment refractory disease and remained alive only
for a few weeks or months. To further analyze the dynam-
ics of ctDNA over time, we compared the peak levels of
mutations and M protein at each relapse (Figure 4). To
facilitate the comparison between patients, we normal-
ized the concentrations of M protein and the ctDNA as
indicated in the legend to Figure 4. Only one mutation per
patient is shown in Figure 4, however, in patients 4 and 5,
mutations in IRF4, TP53 and KRAS behaved in the same
manner indicating that they were all characteristics of the
same aggressive clone. The discrepancy between ctDNA
and M protein in patients 1, 4 and 5 was particularly evi-
dent in the terminal phase when the ratio of ctDNA to M
protein was up to 400-fold higher than at the start of treat-
ment.
We analyzed several aspects of these patients which can
contribute to the marked increase in serum concentrations
of mutations.  Patient 1 and 5 had plasma cells with imma-
ture morphology, whereas patients 1 and 4 had secondary
plasma cell leukemia, with >20% plasma cells in blood.
No plasma cells were found in blood from patient 5. In
two of the patients there was >10% increase in mutated
allele fraction in bone marrow plasma cells from the start
of treatment to the time of terminal disease (34-49% in
patient 2 and 26-52% in patient 5). Thus, several factors
may have contributed to the increased concentrations of
ctDNA that were evident after transformation to a more
aggressive disease. 
Discussion
We studied the serum concentrations of recurrent muta-
tions identified in bone marrow plasma cells from 20
patients with multiple myeloma. Our comprehensive
series of samples covering the entire disease course from
diagnosis to death of several patients provides a unique
insight into the dynamics of ctDNA in relation to disease
activity. The most striking findings were a marked covari-
ation with the concentration of M protein, the gold stan-
dard biomarker to monitor tumor mass in multiple myelo-
ma, and increasing concentrations of ctDNA relative to M
protein as the disease became more aggressive. 
To explain the increase of ctDNA, it is useful to discern
between tumor mass and activity of the cells. The latter
includes a number of functional aspects, such as prolifera-
tive rate and degree of adherence to the bone marrow
environment. M protein is a typical tumor mass marker as
long as the mechanisms of production and secretion of
E.H. Rustad et al.
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Figure 3. Monitoring of three or two mutations in serum. Here, we mon-
itored three (panel A) or two (panel B) recurrent mutations by ddPCR of
serum from the start of treatment until the terminal phase. Treatments:
M: melphalan; P: prednisone; T: thalidomide; V: bortezomib; D: dexam-
ethasone; L: lenalidomide; C: cyclophosphamide; HDT-ASCT: high-dose
melphalan therapy with autologous stem cell transplant
A
B
immunoglobulin are intact. As shown, ctDNA and M pro-
tein seem to reflect tumor mass equivalently during long
periods of the disease when the secretory mechanisms are
operative and cellular functions relatively stable. This pic-
ture changes, however, when there is transformation to a
more proliferative disease with high turnover of cells and
perhaps a larger fraction of non-secretory cells.
Furthermore, myeloma cells may be present in the circula-
tion as shown in two of our patients. Although its clinical
significance is unclear, ctDNA seems to reflect disease
activity and progression differently from M protein.  
Our serum samples were stored for up to 11 years
before analysis. Despite reports of DNA degradation dur-
ing protracted sample storage,28 we found no statistically
significant correlation between DNA yield and storage
time, as shown in the methods section. Furthermore, it is
recommended that ctDNA is analyzed in plasma rather
than serum because of DNA released from leukocytes dur-
ing sample preparation.29 However, to our knowledge,
serum and plasma have not been directly compared in a
clinical setting, and previous studies have successfully
used stored serum samples.30,31 The close covariation
between ctDNA and M protein found in our study adds to
the evidence that stored serum can provide meaningful
results and is a valuable material for the study of ctDNA.
A weakness of this study was the low number of
patients, limiting the generalizability of our results.
Another weakness was the low and variable volume of
serum available for analysis at each time-point, as report-
ed in the methods section and elaborated in the Online
Supplementary Methods. Because the ability of ddPCR to
detect low levels of mutations is primarily limited by the
sample volume and concentration of DNA, the sensitivity
of our ctDNA measurements varied and was suboptimal
in many samples. The potential to detect early relapse and
minimal residual disease by ctDNA was, therefore, most
likely under-estimated in our study. 
Mithraprabhu et al. recently reported the detection and
monitoring of ctDNA in myeloma patients.16 Their design
differed from ours as they sequenced DNA from plasma as
well as bone marrow plasma cells, targeting recurrently
mutated regions in the NRAS, KRAS, BRAF and TP53
genes. Interestingly, they found 24% of mutations exclu-
sively in plasma, consistent with the spatial heterogeneity
of multiple myeloma previously demonstrated by multi-
region DNA sequencing of bone marrow plasma cells.32,33
They also monitored specific mutations by ddPCR in three
to six sequential samples from seven patients16 and our
results are essentially in agreement with their observations. 
There are also apparent discrepancies between the stud-
ies. We detected 97% of mutations in serum when they
had been identified in a time-matched bone marrow sam-
ple, whereas the corresponding number was only 39%
(38/97) in the study by Mithraprabhu et al.16 This may be
explained by the high sensitivity of their procedure as the
majority of mutations they detected in bone marrow plas-
ma cells had a mutated allele fraction between 0.01 and
1%. In comparison, the limit of detection by WES of bone
marrow plasma cells in our study was 2-4 % mutated allele
fraction, which is in line with previous studies using
WES.17,18
There are several potential applications of ctDNA in
multiple myeloma. The mechanisms by which M protein
and ctDNA are released into the bloodstream appear to be
independent of each other. Thus, monitoring the disease
using ctDNA may be possible in situations in which M
protein is not a reliable biomarker, such as in light chain
escape and non-secretory or oligo-secretory disease.6,7,16
Furthermore, non-invasive detection of specific mutations
may be useful to guide the use of targeted drugs such as
BRAF or MEK inhibitors in patients with BRAF, NRAS or
KRAS mutations.22-24
In principle, any tumor-specific DNA sequence such as
a somatic mutation or a translocation breakpoint could be
monitored by ddPCR.12,34,35 Alternatively, targeted sequenc-
ing may be applied directly to plasma or serum DNA to
detect several targets simultaneously.13,30,36 This approach
has the potential to describe tumor clonal evolution over
time and its relation to clinical phenomena such as drug
resistance37,38 and may be preferred in many situations.
The choice of method will depend on the purpose.
Altogether, this study provides detailed insight into the
development of ctDNA levels over long periods of time in
a limited number of patients. Circulating tumor DNA
appears to be a multi-faceted biomarker of mutated cells,
total tumor mass and transformation to a more aggressive
disease in patients with multiple myeloma. However, sev-
eral important questions remain unanswered, including
the potential of ctDNA in minimal residual disease assess-
ment and early detection of relapse. 
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Figure 4. Ratio between serum levels of recurrent mutations and M protein dur-
ing long-term follow-up. Diagnostic serum concentrations of M protein and MAP
kinase mutations were normalized to one for each patient. Subsequent data are
from the time points of peak M protein level at relapses, before a new treatment
was started. The ratio of normalized mutation level to M protein was calculated
for each data point. Patients were included in the figure if the diagnostic and at
least one peak value of ctDNA and M protein were available. Patient 3 was
excluded because of light chain escape, and patient 9 (Online Supplementary
Figure S4A) was excluded because most peak values of ctDNA were too low to
be confidently quantified. 
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